Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
1-[4-(pyridin-4-yloxy)phenyl]-3-[3-(trifluoromethyl)phenyl]urea is a synthetic small molecule belonging to the diarylether class of organic compounds. It has the molecular formula C19H14F3N3O2 and a molecular weight of approximately 373.33 g/mol. The compound is considered experimental, with no approved medical indications or clinical trial activity reported as of now. Its mechanism of action and pharmacological targets are not described in public databases, and there is no evidence it has reached any stage of clinical development or regulatory approval[1][2][3]. No background information on its biological activity, developer, or therapeutic intent is available.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 1-[4-(pyridin-4-yloxy)phenyl]-3-[3-(trifluoromethyl)phenyl]urea.